Vectibix Vs. Erbitux: The Race For A First-Line Colorectal Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.